The firms have begun a validation sudy of the Down syndrome test, which runs on Illumina’s HiSeq platform.
Illumina will provide its DNA analysis technology, Barts will supply tissue samples, and Source BioScience will develop the test.
The company will investigate the use of PacBio's RS platform for use in the test protocol.
After verifying that organ transplant rejection corresponds to a rise in cell-free donor DNA in recipient blood samples, researchers from Stanford University developed a sequencing-based approach for assessing these donor DNA levels.
The startup will use its using next-generation sequencing-based technology for applications aimed at identifying biothreats.
The space is being housed at its headquarters and will run the company's planned Trisomy 21 test.
The molecular diagnostics firm currently has a patent application for a method of using DNA sequencing technology for identifying biomarkers of autoimmune disease.
Enzo plans to seek approval for and market MultiGen's antenatal infectious disease tests in New York and in other US regions.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.